Imago Biosciences Inc Net Income per Employee (IMGO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Imago Biosciences Inc   (NASDAQ: IMGO)
 

Imago Biosciences Inc Net Income per Employee

IMGO's Quarterly Results, Trends, Rankings, Statistics
Imago Biosciences Inc recorded a cumulative net loss of $-26 million during 12 month ending in the third quarter 2022.
The Healthcare sector has seen employees of 339 other companies achieving higher income per employee. While Imago Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4401.


What is Income per Employee Ratio?






IMGO Net Income per Employee (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,201,591 -969,500 -745,182 -323,136 -1,506,136
IMGO's Total Ranking # 4401 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


IMGO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 340
Healthcare Sector # 787
Overall Market # 4401

Net Income per Employee Statistics
High Average Low
$ -323,136 $ -727,936 $ -1,201,591
(Dec 31 2021)   (Sep 30 2022)







Companies with similar Income per Employee for 12 month ending Sep 30 2022, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2022Number of Employees Sep 30 2022


Date modified: 2026-09-08T15:10:46+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.